[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cook Research Incorporated\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,81,106,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100604025","evero-drug-coated-balloon-dcb-randomized-trial-100604025",false,"NCT07144150","EVERO Drug-coated Balloon (DCB) Randomized Trial","Advance Evero™ 18 Everolimus-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter Versus Paclitaxel-coated Ballons in Patients With Femoropopliteal Disease (EVERO Trial)","Inclusion Criteria:\n\n1. Documented PAD with Rutherford classification 2 - 4; and\n2. De novo or restenotic (non-stented) target lesion located in the native superficial femoral artery (SFA), popliteal artery (P1 or P2), or both native SFA and popliteal arteries.\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria\n\n1. Less than 18 years old;\n2. Inability or refusal to give informed consent by the patient or legally authorized representative;\n3. Life expectancy ≤ 12 months, per investigator assessment;\n4. Pregnant (or if absence of pregnancy is not verified by negative pregnancy test within 7 days of planned procedure), lactating, planning to become pregnant within 12 months of the planned procedure, or unwilling to use contraception for 12 months following the planned procedure;\n5. Unable or unwilling to comply with the follow-up schedule; or\n6. Simultaneously participating in another investigational drug or device study unless the patient is at least 30 days beyond the primary endpoint of any previous study.","ALL","18 Years",{"count":19,"type":20},410,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \\[DCB\\]) in the treatment of the femoropopliteal artery lesions in patients with peripheral arterial disease (PAD). Specifically, the Randomized-Controlled Trial (RCT) is designed to demonstrate non-inferior safety and non-inferior effectiveness of the Evero DCB when compared to commercially available paclitaxel DCBs (pDCBs).",[26,27],"Peripheral Vascular Disease","Peripheral Arterial Disease",[29,30,31,32,33,34,35,36,37],"Intermittent claudication","Paclitaxel","Everolimus","Rapamycin","Drug-coated balloon (DCB)","Percutaneous transluminal angioplasty (PTA)","Femoropopliteal artery","Superficial femoral artery (SFA)","Popliteal artery","RECRUITING","2026-07-01",{"date":41,"type":42},"2026-07-02","ACTUAL",{"date":44,"type":42},"2026-04-17",{"date":46,"type":20},"2032-10",{"name":48,"class":49},"Cook Research Incorporated","INDUSTRY",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100508130","european-aortic-data-collection-project-100508130","NCT05896397","European Aortic Data Collection Project","EADC","Inclusion Criteria:\n\n1\\. Patients who will be treated with a Cook CMD\n\nExclusion Criteria:\n\n1. Patients who declare they are unable to complete clinical follow-up visit at the time of enrollment, or\n2. Patients or his\u002Fher legally authorized representative objects to extraction of patient's data from the medical record, or unwilling to sign the Informed Consent.",{"count":58,"type":20},600,"OBSERVATIONAL","The purpose of this study is to evaluate the safety and performance of Cook's various Custom-Made Stent-graft Devices (CMD) used for endovascular treatment of the aorta and related diseases by collecting information on the real-world use of the devices.\n\nThe study results will be used to support the continuation of the CMDs on the market. In addition, the study will support the manufacturers obligation for post market product surveillance as well as Cook's technology development.",[62,63,64,65],"Complex Abdominal Aortic Aneurysm","Thoracoabdominal Aortic Aneurysm","Aortic Arch Aneurysm","Chronic Aortic Dissection",[67,68,69,70,71],"Complex aortic repair","Aortic aneurysm","Aortic dissection","Fenestrated\u002Fbranched endograft","Custom-made endovascular graft","2026-06-03",{"date":74,"type":42},"2026-06-04",{"date":76,"type":42},"2023-05-31",{"date":78,"type":20},"2030-12",{"name":48,"class":49},18,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":90,"studyType":59,"phases":4,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":104,"locationsCount":105},"100507008","post-market-celect-platinum-vena-cava-filter-and-gunther-tulip-retrieval-set-study-100507008","NCT05881798","Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study","Post-Market Celect Platinum Vena Cava Filter and Günther Tulip Retrieval Set Study","Inclusion Criteria:\n\n* A patient dataset is deemed suitable for inclusion if the patient has a procedure where a Celect Platinum Vena Cava Filter is placed\n* Subject has not previously participated in the Cook MDR-2126 study.\n\nExclusion Criteria:\n\n* Patients will be excluded from enrollment if the patient or his\u002Fher legally authorized representative objects to collection and processing of his\u002Fher data or is not willing to sign the Informed Consent.",{"count":89,"type":20},82,"5 Years","This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and performance of the devices throughout their expected lifetime and continued acceptability of the benefit:risk ratio. Additionally, the study intends to evaluate longer-term (i.e., up to 5 years) outcome data while the filter is indwelling.",[93,94,95],"Deep Vein Thrombosis","Venous Thromboembolism","Pulmonary Embolism",[97,98],"Celect Platinum Vena Cava Filter","Gunther Tulip Vena Cava Filter Retrieval Set","2026-04-14",{"date":44,"type":42},{"date":102,"type":42},"2025-06-02",{"date":78,"type":20},{"name":48,"class":49},7,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100429696","zenith-fenestrated-clinical-study-100429696","NCT04875429","Zenith® Fenestrated+ Clinical Study","Zenith® Fenestrated+ Endovascular Graft Clinical Study","Include Criteria:\n\n1. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with a diameter ≥ 55 mm for males and ≥ 50 mm for females\n2. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with a growth rate of ≥ 5 mm in 6 months\n3. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with aortic diameter \\> 2x the normal aortic diameter or saccular aneurysm that warrants treatment in the opinion of the investigator\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Life expectancy \\\u003C 2 years\n3. Pregnant, breast-feeding, or planning to become pregnant within 60 months\n4. Inability or refusal to give informed consent by the patient or legally authorized representative\n5. Unwilling or unable to comply with the follow-up schedule, required clinical assessments, and imaging\n6. Simultaneous participation in another investigation study, unless the patient is at least 30 days beyond the primary endpoint of any previous study",{"count":114,"type":20},105,[23],"The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries.\n\nUp to 60 additional subjects may be enrolled in Continued Access phase of the study",[118,119,120,121],"Aortic Aneurysm, Abdominal","Juxtarenal Aortic Aneurysm","Extent IV Thoracoabdominal","Pararenal Aneurysm",[123,124,125,126],"endovascular","Vascular Diseases","Cardiovascular Diseases","Fenestration","2026-03-19",{"date":129,"type":42},"2026-03-23",{"date":131,"type":42},"2023-12-08",{"date":133,"type":20},"2031-11",{"name":48,"class":49},33,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":144,"conditions":145,"keywords":152,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},"100591940","beacon-tip-sizing-catheter-and-slip-cath-beacon-tip-catheter-study-100591940","NCT06986954","Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study","Inclusion Criteria:\n\n* A patient is deemed suitable for inclusion in this study if the patient undergoes a procedure using an applicable Beacon Tip Catheter.\n\nExclusion Criteria:\n\n* Patient or his\u002Fher legally authorized representative objects to collection and processing of his\u002Fher data, or not willing to accept the use of an Informed Consent waiver or the data protection notice (if utilized).",{"count":143,"type":20},588,"This prospective observational post-market clinical study will collect data in the United States to primarily support the re-launch of the re-designed Beacon Tip Sizing Catheter and Slip-Catheter Beacon Tip Catheter \\& Shuttle Select Slip-Catheter (Visceral and Cerbral) for a Conformité Européenne (CE) Mark application in the European Union (EU). Additionally, the data from this study may be used to support regulatory approval in other countries\u002Fregions.\n\nThe purpose of this clinical study is to evaluate the safety and performance of these catheters in accordance with the Intended Use through the end of index procedure, and through 30 days post procedure, (as applicable as data is available) to ensure an acceptable benefit:risk ratio.",[146,147,148,149,150,151],"Stenosis","Bleed Intracranial","Stroke","TIA","Vascular Malformation","Pseudoaneurysm",[153,154,155,156,157],"Catheter","Beacon","Diagnostic imaging","Device sizing","Beacon tip slip cath","2025-07-15",{"date":160,"type":42},"2025-07-16",{"date":162,"type":42},"2025-04-20",{"date":164,"type":20},"2026-07-31",{"name":48,"class":49},1,""]